MindMed doses first patient in Phase 3 Emerge study of MM120 ODT for MDD

Definium Therapeutics, Inc.

First patient dosed in Phase 3 Emerge study evaluating MM120 ODT 100 µg vs placebo in major depressive disorder.
Primary endpoint: change from baseline in MADRS score at Week 6; ~140 participants expected in U.S.
Topline data from the 12-week double-blind period anticipated in second half of 2026.
Emerge is the third Phase 3 study of MM120 ODT; Voyage and Panorama studies in GAD are already underway.
Phase 2b GAD study showed clinically and statistically significant MADRS improvements after single 100 µg dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.